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Abstract. 
Ifosfamide is an alkylating antineoplastic prodrug used to treat many solid tumors. The 
metabolism of ifosfamide is via CYP450 3A4 and 2B6 and produces active ifosfamide mustard, 
the toxic metabolite acrolein and chloroacetaldehyde (CAA). Additionally, CAA is believed to 
induce proximal tubular dysfunction which results in Fanconi’s syndrome. It is a condition not 
commonly encountered in adults receiving ifosfamide but relatively common in children. 
Herein, we have reported a 25-year-old woman with a history of synovial sarcoma with multi-
ple lung metastasis and repetitive locoregional recurrence. She received chemotherapy with 
high dose ifosfamide as her antineoplastic treatment. Before her 4th cycle of chemotherapy, the 
patient’s pre-chemotherapy evaluation revealed proteinuria, glucosuria, phosphateuria, hypo-
phosphatemia and non-anion gap metabolic acidosis. The above conditions were consistent 
with Fanconi’s syndrome. We treated her with electrolyte supplement and close monitoring of 
the noted laboratory abnormalities. Fortunately, the laboratory abnormality gradually resolved. 
Our case highlights the rare potential complication of ifosfamide, especially in patients who 
had received a high cumulive dose. To avoid this rare but potentially debilitating condition, pa-
tients whose cumulative ifosfamide dose reaches threshold should be closely monitored. 
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中文摘要 
  Ifosfamide 是一種烷化劑型的抗惡性腫瘤的前驅藥物，可以用來治療多種固態腫瘤。
Ifosfamide 代謝主要是依靠 CYP450 3A4 及 2B6，代謝後會產生活性的 ifosfamide mustard，
及其毒性代謝物 acrolein 及 chloroacetaldehyde (CAA)。CAA 被認為會造成近端小管功能
失調，進而引發 Fanconi 氏症。這種情形在成年人中是比較少見的，但在小孩子當中則
是相對比較常見的。在此，我們報告了一位 25 歲女性，本身患有滑液膜惡性肉瘤合併多
處肺轉移及反覆局部復發，他接受高劑量 ifosfamide 做為其抗癌治療，在第四個療程之
前，化療前評估發現其有蛋白尿，糖尿，磷離子尿及非陰離子隙代謝性酸中毒。以上徵
象指其患有 Fanconi 氏症，因此我們幫其補充失衡的電解質，並密切追蹤其異常的檢驗數
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 據。幸運的是，這些異常的檢驗數據慢慢的恢復正常。我們的案例焦點在 ifosfamide 可能
造成的併發症，特別是在那些已經接受了高累積劑量的人。因此，對於那些已經接受
ifosfamide 且其累積劑量已達閾值者，密切追蹤是必需的，其目的是為了避免這個稀少但
卻會使人衰弱的病症。 
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INTRODUCTION 
Nephrotoxicity is a rare but potentially dangerous 
adverse effect of numerous chemotherapeutic agents 
[1]. Ifosfamide is one of the numerous chemothera-
peutic agents which can cause nephrotoxicity in vary-
ing severities. Fanconi’s syndrome is characterized by 
proximal tubule dysfunction which can cause electro-
lyte imbalance leading to even more severe complica-
tion (ex. osteomalacia). Ifosfamide is an alkylating 
antineoplastic prodrug used to treat many solid tumors, 
including sarcomas [2]. It frequently induces Fanco-
ni’s syndrome in children, but rarely in adults [3]. We 
reported a case where the patient received high dose 
ifosfamide to treat synovial sarcoma. Fanconi’s syn-
drome was diagnosed in this patient, and after suc-
cessful treatment, the patient discharged with no fur-
ther electrolyte imbalance. 
 
CASE REPORT 
A 25-year-old woman was admitted to the hospital 
with symptoms of mild shortness of breath and dry 
cough. She had a history of recurrent synovial sar-
coma over the right inguinal area diagnosed 6 years 
earlier, which was treated with surgical excision and 
external beam radiotherapy. However, locoregional 
recurrence was diagnosed 2 months after the primary 
treatment. At that time, she was making regular clinic 
visits for follow-up of the recurrent tumor status. Sur-
gical excision of the recurrent sarcoma was performed 
after follow-up for 18 months. However, repeated lo-
coregional recurrence was diagnosed in the last 3 
years. At this time, the patient’s staging work-up re-
vealed diffuse metastasis over both lungs with mas-
sive left side pleural effusion, together with locore-
gional recurrence involving the contralateral inguinal 
area. She received 2 cycles of high dose ifosfamide 
(3000 mg/m2/day, a 5-day cycle for the 1st cycle, and a 
4-day cycle for the 2nd cycle), and reassessed with 
chest computed tomography and pelvic magnetic res-
onance imaging. Both imaging devices revealed 
shrinkage of tumor size. Furthermore, the patient’s 
symptoms of shortness of breath and dry cough had 
also improved. However, new mixed osteolytic and 
osteoblastic lesions were noted over the thoracic spine 
area. Another 2 courses of high dose ifosfamide was 
planned to be administered, with a total ifosfamide 
dose of 39 g/m2. During the pre-chemotherapy evalua-
tion of the patient’s last chemotherapy, routine blood 
test (hemogram, creatinine, liver enzymes, sodium and 
potassium) revealed no significant abnormality. How-
ever, the routine urine test revealed prominent pro-
teinuria (> 300 mg/dl). Further analysis revealed nor-
mal calcium, chloride, albumin and magnesium, mod-
erate hypophosphatemia (1.5 mg/d/, nl 2.1~4.7 mg/dl). 
Further collection of urine over a 24-hour period re-
vealed proteinuria (2g/day), slightly decreased tubular 
reabsorption of phosphorus (74%, NL > 90%), loss of 
glucose (256 mg/dl) and normal urine chloride, sodi-
um, and potassium. After completion of chemotherapy, 
subsequent blood analysis revealed non-anion gap 
metabolic acidosis (HCO3- 19.3 mmol/L, nl 21~28 
mmol/L), mild hyponatremia (131 mmol/L, nl 135~ 
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 147 mmol/L) and hypokalemia (3.1 mmol/L, nl 3.4~ 
4.7 mmol/L).  
For these abnormalities, we concluded that the pa-
tient suffered from ifosfamide induced tubular dys-
function. Hypokalemia and non-anion gap metabolic 
acidosis were also consistent with type II renal tubular 
dysfunction. Potassium and phosphorus supplement 
was also provided at the same time. The follow-up 
blood and urine test revealed normalization of the 
proteinuria, hypophosphatemia and hypokaemia. 
Thereafter, the patient was discharged following a 
15-day hospital stay. 
 
DISCUSSION 
Ifosfamide requires metabolic activation to form 
the active cytotoxic agent, Ifosfamide mustard [4]. 
This metabolism occurs at CYP450 3A4 and 2B6, and 
the toxic metabolite, acrolein, which was considered 
to be the nephrotoxic, is also released [5,6]. A certain 
percentage of ifosfamide undergoes metabolism 
through an alternative pathway, and another toxic me-
tabolite, chloroacetaldehyde (CAA) is produced and 
also considered to be nephrotoxic [7,8].  
Fanconi’s syndrome is a serious renal complica-
tion associated with ifosfamide, and relatively com-
mon in children (1.4-5%); however, fewer cases have 
been described in adults [3]. Fanconi’s syndrome is 
characterized by proximal tubular dysfunction mani-
fested by a loss of phosphate, bicarbonate, potassium, 
glucose, amino acids, and low molecular weight pro-
tein in the urine [9]. Ifosfamide-induced Fanconi’s 
syndrome is often dose-related, especially when the 
total dose exceeds 45-60 g/m2 in children [2,3].  
Few case reports have described Fanconi’s syn-
drome in adults. One group described a 54-year-old 
man suffering from both Fanconi’s syndrome and di-
abetes insipidus after receiving 44 g/m2 of ifosfamide 
[10]. The abnormal renal function, sodium, potassium, 
and phosphorus serum level returned to normal after 
the patient was supplemented with free water, potas-
sium phosphate, potassium chloride and potassium 
citrate. The non-anion gap metabolic acidosis also 
resolved after sodium bicarbonate supplement. An-
other case study described a 20-year-old man who 
developed Fanconi’s syndrome 3 months after initiat-
ing chemotherapy with ifosfamide, methotrexate and 
doxorubicin [11]. The urinary loss of phosphate led to 
hypophosphatemia, which thereafter induced osteo-
malacia. Phosphate supplement was required in this 
patient. 
Although the mechanism of ifosfamide-induced 
Fanconi’s syndrome remains unclear, current theories 
tend to attribute this phenomenon to the ifosfamide 
toxic metabolite, CAA [2]. After it is metabolized via 
CYP450 3A4 and 2B6, ifosfamide is converted to 
ifosfamide mustard and its toxic metabolite, acrolein 
and CAA [7,8]. Acrolein can be completely neutral-
ized by MESNA, so its toxicity can therefore be pre-
vented by MESNA. However, CAA has low reactivity 
to MESNA, which results in accumulation and toxici-
ty to proximal tubules [2,12]. At subcellular levels, 
CAA may decrease the glutathione and adenosine tri-
phosphate (ATP) levels by inhibiting the activity of 
V-ATPase and NA+/K+-ATPase [9,13]. Cellular en-
docytosis at the proximal tubule is a dependent pro-
cess, so when the ATP level decreases, the reabsorp-
tion in the proximal tubule is correspondingly reduced. 
V-ATPase plays a crucial role in intracellular vesicle 
trafficking. By inhibiting V-ATPase, intracellular pro-
tein processing and endocytosis are both disturbed 
[13].  
There is no established treatment for Fanconi’s 
syndrome. However, N-acetylcysteine (NAC) was 
demonstrated to have certain benefit in animal models 
[14,15]. It has been shown that ifosfamide induced 
oxidative damage to the kidney by depleting glutathi-
one levels with CAA [14,15]. Cells exposed to a large 
dose of ifosfamide or those that have lower concentra-
tions of glutathione experience more toxicity [2]. 
NAC is an antidote, thereby working as a precursor 
and substrate to enhance the biosynthesis of glutathi-
one, and may reduce the toxicity of CAA [15]. NAC 
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 successfully prevented ifosfamide-induced nephrotox-
icity in rats [14]. Further research in humans is re-
quired to determine whether NAC is an adequate an-
tidote for ifosfamide-induced toxicity without com-
promising its antineoplastic activity.  
In conclusion, this 25-year-old woman presented 
with proteinuira, hypophosphatemia, glucosuria, and 
non-anion gap metabolic acidosis after treatment with 
a total dose of 39 g/m2 ifosfamide. Fanconi’s syn-
drome was suspected. After 15 days hospital stay and 
treatment, the patient was discharged with complete 
recovery. No established treatment for ifosfamide- 
induced Fanconi’s syndrome was demonstrated, and 
therapeutic options were limited. The mechanism of 
ifosfamide-induced Fanconi’s syndrome was not fully 
elucidated in our patient, which made this case diffi-
cult to manage. Hence, among patients who receive 
ifosfamide, it would be beneficial to closely monitor 
renal function, and electrolyte and routine urine test 
are furthermore mandatory, particularly when the ac-
cumulated dose exceeds 45 g/m2. 
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